US FDA approves GSK's Nelkarmi (neladalkib) for pretreated ALK-positive lung cancer
What's the deal? On 17 November 2026, the US Food and Drug Administration granted accelerated approval to Nelkarmi (neladalkib), an oral next-generation ALK inhibitor, for adults with locally advanced or metastatic ALK-positive non-small cell lung cancer (NSCLC) who have already been treated with at least one earlier ALK-targeted therapy. It is the second lung-cancer medicine approved for GSK this year, and the second from the pipeline of Nuvalent — the US biotech GSK acquired for $10.6B in July 2026 — following Jideytro (zidesamtinib) earlier in 2026.
The data: The approval is based on ALKOVE-1, a phase I/II single-arm trial. Among 67 patients whose only prior ALK therapy was alectinib, the confirmed overall response rate was 49%, with 76% of responders maintaining their response for at least 6 months and 52% for at least 12 months. Among 155 more heavily pretreated patients (two or more prior ALK inhibitors plus chemotherapy), the response rate was 32%, with 69% and 51% of responders maintaining responses for 6 and 12 months respectively. In 20 patients with measurable brain metastases at baseline, the intracranial response rate was 55%, including 25% complete responses.
Why it matters: ALK-positive NSCLC is a form of lung cancer driven by a specific genetic change, often affecting younger people who have never smoked. The disease commonly spreads to the brain, and tumours develop resistance to existing ALK inhibitors over time. Nelkarmi was designed to cover a broad range of resistance mutations and to cross the blood-brain barrier. The approval came ahead of the original FDA target action date of 27 November 2026, and follows Breakthrough Therapy and Orphan Drug designations and a priority review.
Read more: GSK, 17 November 2026 · FDA, 17 November 2026